Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
Z0021001
Celiac Disease Phase II
- 8.4 weeks
- 1st site activated in Canada - 4th site activated worldwide and Canadian FPI - 2nd patient enrolled globally
1366-0031
Scleroderma Phase II
- 8.5 weeks
- 3rd site activated in Canada
ACT17746
Ulcerative Colitis Phase II
- 15 weeks
- 1st site activated in Canada
ACT17746
Ulcerative Colitis Phase II
- 16 weeks
- 2nd site activated in Canada
AZUR-2
Colorectal Cancer Phase III
- 8 weeks
- 2nd site activated worldwide
C4901001
Solid Tumors Phase IA
- 8.2 weeks
- 1st site activated in Canada, 3rd site activated worldwide and 2nd patient enrolled in Canada
C4901001
Solid Tumors Phase IA
- 7 weeks
- 2nd site activated in Canada and Canadian FPI
C4901001
Solid Tumors Phase IA
- 9.8 weeks
EFC17757
Graft Versus Host Disease Phase II/III
- 10.6 weeks
- Canadian FPI and 3rd patient enrolled globally
EFC17757
Graft Versus Host Disease Phase II/III
- 11.6 weeks
- 2nd site activated in Canada and 4th site activated worldwide
EFC17757
Graft Versus Host Disease Phase II/III
- 15.4 weeks
- 3rd site activated in Canada and 6th site activated worldwide
EVEREST
Nasal Polyps with Asthma Phase IIIb
- 8.4 weeks
- 2nd site activated in Canada and 2nd patient enrolled in Canada
EVEREST
Nasal Polyps with Asthma Phase IIIb
- 13.2 weeks
- 3rd site activated in Canada
Inavo121
Breast Cancer Phase III
- 13.4 weeks
- 1st site activated in Canada
Inavo121
Breast Cancer Phase III
- 19.2 weeks
- 2nd site activated in Canada
Inavo121
Breast Cancer Phase III
- 19 weeks
- 3rd site activated in Canada
Inavo122
Breast Cancer Phase III
- 16.4 weeks
- 1st site activated in Canada
Inavo122
Breast Cancer Phase III
- 9 weeks
- 2nd site activated in Canada
KRAS
Lung Cancer Phase III
- 11.6 weeks
- 1st site activated in Canada
KRAS
Lung Cancer Phase III
- 8.6 weeks
- 2nd site activated in Canada
KRAS
Lung Cancer Phase III
- 7.2 weeks
- 3rd site activated in Canada
VICTORION-1
Cardiology Phase III
- 12.8 weeks
- 1st public site activated in Canada
VICTORION-1
Cardiology Phase III
- 6.2 weeks
EFC15951
Myeloma Phase III
- 19.1 weeks
- Canadian regulatory delay 1st site activated in Canada
EFC15951
Myeloma Phase III
- 21.9 weeks
- Canadian regulatory delay 2nd site activated in Canada